Microsoft and 1910 genetics partner to build the infrastructure layer for drug discovery and development using ai and high-performance computing

Boston--(business wire)--1910 genetics (or “1910”), the only biotechnology company advancing small and large molecule drug discovery with a multimodal ai platform powered by laboratory automation, today announced a new five-year commercial agreement and go-to-market collaboration with microsoft to harness advanced artificial intelligence (ai) and next-generation, high-performance computing (hpc) to reverse 70 years of declining pharmaceutical r&d productivity. 1910 will combine its massive.
MSFT Ratings Summary
MSFT Quant Ranking